20,984 Shares in Abbott Laboratories (NYSE:ABT) Bought by Impact Capital Partners LLC

Impact Capital Partners LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,984 shares of the healthcare product maker’s stock, valued at approximately $2,374,000.

A number of other large investors have also recently bought and sold shares of the company. Noble Wealth Management PBC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. NewSquare Capital LLC boosted its holdings in shares of Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after purchasing an additional 105 shares in the last quarter. Rialto Wealth Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter valued at $29,000. Peterson Financial Group Inc. bought a new stake in shares of Abbott Laboratories during the 3rd quarter worth $32,000. Finally, Wingate Wealth Advisors Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at about $34,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ABT shares. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $135.00 target price on shares of Abbott Laboratories in a research report on Tuesday, January 21st. Stifel Nicolaus upped their price target on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. The Goldman Sachs Group raised their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Finally, Bank of America upped their target price on Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $137.94.

Abbott Laboratories Trading Down 1.8 %

Shares of ABT stock opened at $130.29 on Thursday. The company has a market cap of $225.97 billion, a P/E ratio of 17.03, a PEG ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The stock has a 50 day simple moving average of $126.57 and a two-hundred day simple moving average of $119.21. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.03 billion. During the same period in the prior year, the firm earned $1.19 earnings per share. Abbott Laboratories’s revenue was up 7.2% on a year-over-year basis. Research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.81%. Abbott Laboratories’s payout ratio is currently 30.85%.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the transaction, the executive vice president now owns 74,381 shares of the company’s stock, valued at $10,277,222.77. The trade was a 1.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares of the company’s stock, valued at $4,417,294.90. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 116,449 shares of company stock valued at $15,463,316. Company insiders own 0.47% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.